factual

Generics Only Need Show Bioequivalence

Hatch-Waxman's key reform allowed generic companies to rely on the brand-name drug's already-proven safety and efficacy: the brand must show the drug is safe and works, but the generic only has to show bioequivalence—that its product is the same as the approved drug—avoiding the absurdity of repeating years of clinical trials on an identical chemical.

factualpending

Speaker

Robin Feldman

Evidence Quote

“The generic just has to show bio-equivalence. So, in simplified terms, the first company has to show that the drug is safe and works. The second company just has to say, 'I'm the same. Me, too.'”

Source

Robin Feldman on Drug Patents, Generics, and Drug Wars— EconTalk
Created: 6/13/2026, 12:11:23 AM

Your notes

Loading notes...